YOLFTbeta
Nanexa AB

Nanexa AB

NANEXA · ST · Healthcare / Drug Manufacturers - Specialty & Generic

10.08SEK+0.16 (+1.61%)

Price History

Full chart

Market Stats

Previous Close9.92
Open9.87
Day Range9.72 – 10.14
52-Week Range1.40 – 15.50
Volume694.72K
Market Cap1.91B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.13
Dividend Yield0.00%
Beta1.77
50-Day Avg5.56
200-Day Avg4.25

About

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk to evaluate PharmaShell technology; and Moderna for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. David Westberg
  • Employees17
  • HeadquartersVirdings Allé 2, Uppsala, Sweden, 75450, Sweden
  • Websitehttps://nanexa.com

Leadership

  • Mr. David WestbergChief Executive Officer · b. 1960
  • Mr. Marten RoothCo-Founder & CTO · b. 1977
  • Mr. Anders JohanssonCo-Founder & Head of Intellectual Property · b. 1976
  • Ms. Cecilia Danckwardt-LilliestromChief Financial Officer · b. 1961
  • Mr. Mikael AspHead of QA & Special Advisor · b. 1962
  • Mr. Joel HellrupHead of Pharmaceutical R&D · b. 1983
  • Polla RoufHead of ALD R&D
  • Ms. Bridget Lacey B.Sc.Chief Business Officer
  • Mr. Otto Skolling M.ScDirector of Business Development · b. 1961

Financials

Income Statement

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.48M658.70K280.00K105.00K318.84K1.71M2.37M2.37M2.86M29.33M24.36M36.15M
Growth (%)--55.52%-57.49%-62.50%+203.66%+436.32%+38.42%+0.30%+20.47%+925.42%-16.93%+48.39%
Cost of Revenue256.99K-1.55M-1.74M-3.15M-3.83M-7.02M-18.49M-1.94M-542.00K-29.83M-22.33M45.00M
Gross Profit1.22M2.21M2.02M3.25M4.15M8.73M20.86M4.31M3.40M59.16M46.69M-8.85M
Gross Margin82.65%335.97%722.86%3100.00%1301.59%510.53%881.24%181.63%118.95%201.72%191.67%-24.49%
Operating Expense2.15M6.22M8.34M11.10M15.19M21.44M42.35M40.13M61.38M135.78M72.75M6.61M
Operating Income-922.00K-4.01M-6.32M-7.85M-11.04M-12.71M-21.49M-35.82M-57.98M-76.63M-26.06M-15.46M
Operating Margin-62.26%-608.93%-2255.71%-7472.38%-3462.24%-743.22%-907.86%-1508.89%-2027.31%-261.28%-106.98%-42.77%
EBITDA-847.00K-3.27M-5.36M-6.19M-9.79M-10.81M-16.28M-32.92M-53.86M-70.79M-18.99M-2.92M
EBITDA Margin-57.19%-496.28%-1913.21%-5898.10%-3069.88%-632.40%-687.96%-1386.60%-1883.18%-241.39%-77.94%-8.08%
Net Income-928.00K-4.13M-6.35M-7.97M-11.17M-12.95M-21.74M-36.00M-58.57M-76.40M-24.91M-11.39M
Net Income Margin-62.66%-626.39%-2267.50%-7591.43%-3503.01%-757.31%-918.29%-1516.39%-2047.94%-260.50%-102.23%-31.50%
R&D--723.17K881.69K1.06M1.56M2.73M13.70M6.39M9.07M5.30M13.64M
R&D as % of Total Revenue--258.28%839.70%332.46%91.05%115.38%577.00%223.53%30.93%21.74%37.74%
Interest Expense-115.75K33.29K124.12K134.61K249.00K255.00K186.00K666.00K487.00K461.00K3.12M
Interest Expense % of Total Revenue-17.57%11.89%118.21%42.22%14.56%10.77%7.83%23.29%1.66%1.89%8.62%

Balance Sheet

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.59M7.79M20.59M33.16M27.90M35.44M53.69M165.00M170.19M132.26M91.82M138.14M
Total Liabilities1.12M1.73M3.62M5.71M11.61M10.56M10.34M13.70M61.10M36.43M20.90M36.61M
Total Equity1.47M6.07M16.96M27.46M16.29M24.88M43.35M151.29M109.10M95.83M70.92M101.53M
Cash1.73K3.29M13.24M21.77M10.75M11.38M12.69M105.66M81.18M15.17M10.29M8.17M
Total Debt349.96K351.46K1.91M3.50M5.82M5.16M3.89M3.83M6.27M4.03M3.71M2.20M
Net Debt348.23K-2.94M-11.33M-18.26M-4.93M-6.22M-8.80M-101.83M-74.91M-11.14M-6.59M-5.97M

Cash Flow

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow563.99K-3.29M-6.41M-5.07M-6.76M-9.42M-16.83M-25.13M-7.87M-42.66M-26.43M-1.46M
Investing Cash Flow-1.26M-1.75M-2.45M-6.46M-6.58M-10.65M-20.80M-25.79M-35.42M-34.25M-28.12M-24.75M
Financing Cash Flow524.94K8.33M18.81M20.05M2.32M20.70M38.94M143.89M18.81M60.89M-327.00K60.49M
Capital Expenditure01.75M2.45M6.46M6.58M10.65M20.80M25.79M35.42M34.25M28.12M24.75M
Free Cash Flow563.99K-5.04M-8.85M-11.53M-13.33M-20.07M-37.63M-50.92M-43.29M-76.91M-54.55M-26.21M
FCF to OCF100.00%153.00%138.22%227.37%197.32%213.15%223.61%202.63%550.03%180.29%206.39%1792.75%

Earnings

Report DateAug 20, 2020Nov 12, 2020Feb 18, 2021May 6, 2021Aug 20, 2021Nov 10, 2021Feb 17, 2022Apr 20, 2022Aug 26, 2022Oct 25, 2022Feb 16, 2023May 4, 2023Aug 23, 2023Nov 20, 2023Feb 21, 2024May 3, 2024Aug 27, 2024Nov 7, 2024Feb 19, 2025May 15, 2025Jun 30, 2025Oct 21, 2025Dec 31, 2025May 4, 2026Jun 30, 2026
EPS Estimate-------------------------
EPS Actual-0.31-0.18-0.34-0.27-0.33-0.26-0.26-0.24-0.32-0.24-0.35-0.14-0.16-0.11-0.52-0.02-0.04-0.03-0.09-0.06-0.04-0.080.09-0.08-0.07
Surprise-------------------------
Timing--Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hours-Pre-market-Pre-market-

Key Statistics & Ratios

Market Cap1.91B
Enterprise Value998.94M
Trailing P/E0.00
Forward P/E0.00
Price / Sales56.37
Price / Book7.91
EPS-0.13
Book Value0.696
Revenue (TTM)33.85M
Gross Profit (TTM)20.94M
EBITDA-15.75M
Profit Margin-72.53%
Operating Margin-839.30%
Return on Equity-22.04%
Return on Assets-9.85%
Shares Outstanding191.04M
Shares Float146.26M
Beta1.77
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%